SAREPTA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense, after Tax
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Payment Arrangement, Expense, after Tax of $28.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2026-06-30 was $28.03M, a 32.65% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2026-03-31 was $33.67M, a 27.67% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2025-12-31 was $34.51M, a 37.58% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2025-09-30 was $16.40M, a 66.54% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for fiscal 2025 was $139.08M, a 32.20% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for fiscal 2024 was $205.13M, a 12.39% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for fiscal 2023 was $182.51M, a 21.67% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, expense, after tax for fiscal 2022 was $233.02M.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.03M 10-Q · filed 2026-08-05 | $61.70M 10-Q · filed 2026-08-05 | $96.21M derived: sum of 3 quarters · filed 2026-08-05 | $112.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $33.67M 10-Q · filed 2026-05-06 | $68.18M derived: sum of 2 quarters · filed 2026-05-06 | $84.58M derived: sum of 3 quarters · filed 2026-05-06 | $126.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $34.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $50.90M derived: sum of 2 quarters · filed 2026-03-02 | $92.52M derived: sum of 3 quarters · filed 2026-08-05 | $139.08M 10-K · filed 2026-03-02 |
| 2025-09-30 | $16.40M 10-Q · filed 2025-11-06 | $58.01M derived: sum of 2 quarters · filed 2026-08-05 | $104.57M 10-Q · filed 2025-11-06 | $159.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $41.62M 10-Q · filed 2026-08-05 | $88.17M 10-Q · filed 2026-08-05 | $143.45M derived: sum of 3 quarters · filed 2026-08-05 | $192.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $46.56M 10-Q · filed 2026-05-06 | $101.83M derived: sum of 2 quarters · filed 2026-05-06 | $150.83M derived: sum of 3 quarters · filed 2026-05-06 | $206.48M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $55.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $104.27M derived: sum of 2 quarters · filed 2026-03-02 | $159.93M derived: sum of 3 quarters · filed 2026-03-02 | $205.13M 10-K · filed 2026-03-02 |
| 2024-09-30 | $49.00M 10-Q · filed 2025-11-06 | $104.65M derived: sum of 2 quarters · filed 2025-11-06 | $149.85M 10-Q · filed 2025-11-06 | $195.68M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $55.65M 10-Q · filed 2025-08-06 | $100.86M 10-Q · filed 2025-08-06 | $146.69M derived: sum of 3 quarters · filed 2026-03-02 | $194.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $45.20M 10-Q · filed 2025-05-06 | $91.03M derived: sum of 2 quarters · filed 2026-03-02 | $139.09M derived: sum of 3 quarters · filed 2026-03-02 | $186.47M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $45.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $93.89M derived: sum of 2 quarters · filed 2026-03-02 | $141.26M derived: sum of 3 quarters · filed 2026-03-02 | $182.51M 10-K · filed 2026-03-02 |
| 2023-09-30 | $48.06M 10-Q · filed 2024-11-06 | $95.44M derived: sum of 2 quarters · filed 2024-11-06 | $136.69M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $47.38M 10-Q · filed 2024-08-07 | $88.63M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $41.25M 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | $233.02M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |